%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Amna Malik, Emily Adland, Leana Laker, Henrik Kløverpris, Rabiah Fardoos, Julia Roider, Mai C. Severinsen, Fabian Chen, Lynn Riddell, Anne Edwards, Søren Buus, Pieter Jooste, Philippa C. Matthews, Philip J. R. Goulder
Immunodominant cytomegalovirus-specific CD8+ T-cell responses in sub-Saharan African populations
www.plosone.org
www.plosone.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 11 0 R/Annots 12 0 R/Contents 13 0 R/TrimBox[0 0 612 792]>>
endobj
12 0 obj
[14 0 R 15 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R 31 0 R 32 0 R 33 0 R]
endobj
14 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref001)>>
endobj
15 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref002)>>
endobj
16 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref003)>>
endobj
17 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref001)>>
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref004)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref006)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref007)>>
endobj
21 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref008)>>
endobj
22 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref010)>>
endobj
23 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref011)>>
endobj
24 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref012)>>
endobj
25 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref013)>>
endobj
26 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref018)>>
endobj
27 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref011)>>
endobj
28 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref019)>>
endobj
29 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.t001)>>
endobj
30 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref020)>>
endobj
31 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref021)>>
endobj
32 0 obj
<>/Border[0 0 0]/Dest(Rpone.0189612.ref022)>>
endobj
33 0 obj
<>/Border[0 0 0]/A 34 0 R>>
endobj
34 0 obj
<>
endobj
13 0 obj
[35 0 R 36 0 R 37 0 R 38 0 R 39 0 R 40 0 R 41 0 R 42 0 R 43 0 R 44 0 R 45 0 R 46 0 R 47 0 R 48 0 R 49 0 R 50 0 R 51 0 R 52 0 R 53 0 R 54 0 R 55 0 R]
endobj
35 0 obj
<>stream
q
0.83 0.64 0.02 0 k
407.452 674.9858 m
412.1575 674.9858 l
h
f*
421.0583 674.9858 m
425.7638 674.9858 l
h
f*
240.378 649.0205 m
245.0835 649.0205 l
h
f*
549.1276 649.0205 m
553.8331 649.0205 l
h
f*
363.515 622.9984 m
368.2772 622.9984 l
h
f*
373.4362 622.9984 m
378.1984 622.9984 l
h
f*
221.7827 596.9764 m
226.5449 596.9764 l
h
f*
464.3717 596.9764 m
469.1339 596.9764 l
h
f*
474.2929 596.9764 m
483.8173 596.9764 l
h
f*
453.2031 571.011 m
462.6709 571.011 l
h
f*
460.8 558.0283 m
470.2677 558.0283 l
h
f*
511.4268 519.0236 m
520.9512 519.0236 l
h
f*
526.1102 519.0236 m
535.6346 519.0236 l
h
f*
526.7339 441.0142 m
536.2583 441.0142 l
h
f*
496.1764 428.0315 m
505.7008 428.0315 l
h
f*
306.4819 274.9039 m
335.622 274.9039 l
h
f*
343.8425 255.9118 m
353.3669 255.9118 l
h
f*
333.1843 236.9197 m
342.7087 236.9197 l
h
f*
347.9811 191.9055 m
357.5055 191.9055 l
h
f*
0 g
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 706.0535 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 689.1023 cm
BT
/F7 1 Tf
1 TL
-0.009 Tc
0 0 Td
(Human)Tj
3.2938 0 Td
(cytomegalovirus)Tj
6.701 0 Td
(\(CMV\))Tj
3.1295 0 Td
(is)Tj
0.8334 0 Td
(a)Tj
0.6519 0 Td
(ubiquitous)Tj
4.4674 0 Td
(beta)Tj
1.8595 0 Td
(human)Tj
3.0557 0 Td
(herpesvirus.)Tj
4.989 0 Td
(The)Tj
1.7688 0 Td
(prevalence)Tj
4.439 0 Td
(of)Tj
-35.189 -1.3039 Td
(CMV)Tj
2.4547 0 Td
(infection)Tj
3.7474 0 Td
(is)Tj
0.8391 0 Td
(very)Tj
1.8992 0 Td
(high)Tj
1.9899 0 Td
(in)Tj
1.0261 0 Td
(developing)Tj
4.5524 0 Td
(countries)Tj
3.9005 0 Td
([)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(])Tj
1.3606 0 Td
([)Tj
0.83 0.64 0.02 0 k
(2)Tj
0 g
(])Tj
1.3606 0 Td
(and)Tj
1.7178 0 Td
(is)Tj
0.8334 0 Td
(endemic)Tj
3.6226 0 Td
(in)Tj
1.0262 0 Td
(sub-Saharan)Tj
5.1363 0 Td
(Afri-)Tj
-35.4668 -1.2982 Td
(can)Tj
1.61 0 Td
(populations)Tj
4.8983 0 Td
(with)Tj
1.9729 0 Td
(almost)Tj
2.8573 0 Td
(two-thirds)Tj
4.3653 0 Td
(of)Tj
1.0034 0 Td
(infants)Tj
2.9311 0 Td
(infected)Tj
3.3788 0 Td
(by)Tj
1.1736 0 Td
(3)Tj
0.6859 0 Td
(months)Tj
3.2542 0 Td
(of)Tj
1.0035 0 Td
(age)Tj
1.5307 0 Td
(and)Tj
1.7121 0 Td
(85%)Tj
1.9162 0 Td
(infected)Tj
-34.2933 -1.2983 Td
(by)Tj
1.1678 0 Td
(a)Tj
0.652 0 Td
(year)Tj
1.8822 0 Td
([)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(].)Tj
1.5817 0 Td
(By)Tj
1.2472 0 Td
(adolescence)Tj
4.9039 0 Td
(CMV)Tj
2.4548 0 Td
(infection)Tj
3.7474 0 Td
(is)Tj
0.8391 0 Td
(virtually)Tj
3.4752 0 Td
(universal)Tj
3.8097 0 Td
(in)Tj
1.0262 0 Td
(sub-Saharan)Tj
5.1363 0 Td
(Africa)Tj
2.6532 0 Td
([)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(].)Tj
-0.004 Tc
-33.3805 -1.3039 Td
(CMV)Tj
2.4718 0 Td
(infection)Tj
3.7927 0 Td
(is)Tj
0.8504 0 Td
(usually)Tj
3.016 0 Td
(asymptomatic)Tj
5.8564 0 Td
(but)Tj
1.5477 0 Td
(can)Tj
1.627 0 Td
(lead)Tj
1.8539 0 Td
(to)Tj
1.0261 0 Td
(severe)Tj
2.6759 0 Td
(clinical)Tj
3.0784 0 Td
(complications)Tj
5.8394 0 Td
(in)Tj
-34.8319 -1.2983 Td
(patients)Tj
3.3675 0 Td
(who)Tj
1.9389 0 Td
(are)Tj
1.4456 0 Td
(immunocompromi)Tj
7.7272 0 Td
(sed)Tj
1.5307 0 Td
([)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(6)Tj
0 g
(].)Tj
2.5909 0 Td
(We)Tj
1.61 0 Td
(focus)Tj
2.3301 0 Td
(here)Tj
1.9616 0 Td
(on)Tj
1.2756 0 Td
(the)Tj
1.474 0 Td
(CMV-specific)Tj
5.7883 0 Td
(CD8+)Tj
2.6759 0 Td
(T-)Tj
-35.7163 -1.2982 Td
(cell)Tj
1.559 0 Td
(response,)Tj
3.9571 0 Td
(since)Tj
2.2451 0 Td
(firstly,)Tj
2.7325 0 Td
(T-cell)Tj
2.5172 0 Td
(immunity)Tj
4.2236 0 Td
(plays)Tj
2.2337 0 Td
(an)Tj
1.2019 0 Td
(important)Tj
4.2859 0 Td
(role)Tj
1.7632 0 Td
(in)Tj
1.0374 0 Td
(controlling)Tj
4.6488 0 Td
(CMV)Tj
2.4718 0 Td
(infec-)Tj
-34.8772 -1.304 Td
(tion)Tj
1.8425 0 Td
([)Tj
0.83 0.64 0.02 0 k
(7)Tj
0 g
(])Tj
1.3719 0 Td
(and)Tj
1.7291 0 Td
(preventing)Tj
4.5411 0 Td
(symptomatic,)Tj
5.6466 0 Td
(disseminated)Tj
5.4765 0 Td
(CMV)Tj
2.4718 0 Td
(disease)Tj
3.016 0 Td
([)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(])Tj
2.846 0 Td
(and)Tj
1.7291 0 Td
(secondly,)Tj
3.9402 0 Td
(the)Tj
1.4683 0 Td
(fre-)Tj
-36.0791 -1.2982 Td
(quency)Tj
3.101 0 Td
(of)Tj
1.0148 0 Td
(CMV-specific)Tj
5.794 0 Td
(T-cell)Tj
2.5228 0 Td
(responses)Tj
4.0932 0 Td
(is)Tj
0.8504 0 Td
(unusually)Tj
4.0932 0 Td
(high,)Tj
2.2337 0 Td
(on)Tj
1.2756 0 Td
(average)Tj
3.2258 0 Td
(10%)Tj
1.9275 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(CD4+)Tj
2.6759 0 Td
(and)Tj
-35.2911 -1.2983 Td
(CD8+)Tj
2.6758 0 Td
(T-cell)Tj
2.5172 0 Td
(memory)Tj
3.617 0 Td
(compartments)Tj
6.0434 0 Td
(in)Tj
1.0375 0 Td
(adult)Tj
2.2507 0 Td
(peripheral)Tj
4.3199 0 Td
(blood)Tj
2.5172 0 Td
([)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(].)Tj
2.0749 0 Td
(High)Tj
2.2451 0 Td
(magnitude)Tj
4.5354 0 Td
(CMV-)Tj
-33.8341 -1.2983 Td
(specific)Tj
3.1917 0 Td
(T-cell)Tj
2.5172 0 Td
(responses)Tj
4.0932 0 Td
(have)Tj
2.0636 0 Td
(also)Tj
1.7688 0 Td
(been)Tj
2.1203 0 Td
(demonstrated)Tj
5.76 0 Td
(in)Tj
1.0374 0 Td
(infancy)Tj
3.1862 0 Td
([)Tj
0.83 0.64 0.02 0 k
(12)Tj
0 g
(].)Tj
-24.5422 -1.3039 Td
(Although)Tj
4.0081 0 Td
(the)Tj
1.4684 0 Td
(prevalence)Tj
4.4843 0 Td
(of)Tj
1.0148 0 Td
(CMV)Tj
2.4718 0 Td
(is)Tj
0.8504 0 Td
(high)Tj
2.0069 0 Td
(in)Tj
1.0318 0 Td
(sub-Saharan)Tj
5.1931 0 Td
(African)Tj
3.2371 0 Td
(populations)Tj
4.9493 0 Td
(from)Tj
2.2053 0 Td
(infancy,)Tj
-34.1175 -1.2982 Td
(most)Tj
2.2053 0 Td
(previous)Tj
3.651 0 Td
(studies)Tj
2.982 0 Td
(defining)Tj
3.5603 0 Td
(CMV-specific)Tj
5.7883 0 Td
(CD8+)Tj
2.6759 0 Td
(T-cell)Tj
2.5228 0 Td
(epitopes)Tj
3.532 0 Td
(have)Tj
2.0636 0 Td
(focused)Tj
3.2768 0 Td
(on)Tj
1.2756 0 Td
(human)Tj
-33.5336 -1.2983 Td
(leukocyte)Tj
4.0195 0 Td
(antigen)Tj
3.2031 0 Td
(\(HLA\))Tj
2.8913 0 Td
(class)Tj
2.0466 0 Td
(I)Tj
0.5613 0 Td
(alleles)Tj
2.6021 0 Td
(that)Tj
1.7745 0 Td
(are)Tj
1.4514 0 Td
(common)Tj
3.8437 0 Td
(in)Tj
1.0375 0 Td
(white)Tj
2.4208 0 Td
(populations)Tj
4.9492 0 Td
([)Tj
0.83 0.64 0.02 0 k
(13)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(18)Tj
0 g
(].)Tj
3.5433 0 Td
(The)Tj
-34.3443 -1.3039 Td
(aim)Tj
1.7404 0 Td
(of)Tj
1.0148 0 Td
(this)Tj
1.6724 0 Td
(study)Tj
2.3925 0 Td
(was)Tj
1.6951 0 Td
(therefore)Tj
3.8551 0 Td
(to)Tj
1.0261 0 Td
(identify)Tj
3.2938 0 Td
(the)Tj
1.4684 0 Td
(immunodominant)Tj
7.6648 0 Td
(CMV-specific)Tj
5.7883 0 Td
(CD8+)Tj
2.6759 0 Td
(T)Tj
0.8334 0 Td
(cell)Tj
-35.121 -1.2983 Td
(epitopes)Tj
3.5319 0 Td
(in)Tj
1.0375 0 Td
(a)Tj
0.6519 0 Td
(study)Tj
2.3925 0 Td
(cohort)Tj
2.8516 0 Td
(of)Tj
1.0148 0 Td
(African)Tj
3.2371 0 Td
(subjects.)Tj
3.6057 0 Td
(In)Tj
1.1112 0 Td
(order)Tj
2.4207 0 Td
(to)Tj
1.0205 0 Td
(achieve)Tj
3.1748 0 Td
(this,)Tj
1.8992 0 Td
(we)Tj
1.3266 0 Td
(determined)Tj
4.8529 0 Td
(in)Tj
/F11 1 Tf
0 Tc
1.0374 0 Td
(>)Tj
/F7 1 Tf
-0.004 Tc
(250)Tj
-35.1663 -1.2982 Td
(Southern)Tj
3.9004 0 Td
(African)Tj
3.2371 0 Td
(individuals)Tj
4.6488 0 Td
(the)Tj
1.4684 0 Td
(ex)Tj
1.1055 0 Td
(vivo)Tj
1.9048 0 Td
(responses)Tj
4.0932 0 Td
(by)Tj
1.1849 0 Td
(Interferon)Tj
4.337 0 Td
(gamma)Tj
3.1918 0 Td
(\(IFN-)Tj
/F12 1 Tf
(\r)Tj
/F7 1 Tf
(\))Tj
3.3108 0 Td
(enzyme-)Tj
-32.3827 -1.304 Td
(linked)Tj
2.7269 0 Td
(immunospot)Tj
5.3971 0 Td
(\(ELISpot)Tj
3.8041 0 Td
(assay\))Tj
2.6022 0 Td
(to)Tj
1.0261 0 Td
(a)Tj
0.6576 0 Td
(panel)Tj
2.3868 0 Td
(of)Tj
1.0148 0 Td
(overlapping)Tj
4.9719 0 Td
(peptides)Tj
3.5546 0 Td
(spanning)Tj
3.9118 0 Td
(the)Tj
1.4684 0 Td
(pp65,)Tj
-33.5223 -1.2982 Td
(72-kDa)Tj
3.1861 0 Td
(immediate)Tj
4.5014 0 Td
(early)Tj
2.1486 0 Td
(\(IE-1\))Tj
2.6362 0 Td
(and)Tj
1.7291 0 Td
(86-kDa)Tj
3.1918 0 Td
(immediate)Tj
4.5014 0 Td
(early)Tj
2.1487 0 Td
(\(IE-2\))Tj
2.6362 0 Td
(CMV)Tj
2.4718 0 Td
(proteins.)Tj
3.736 0 Td
(These)Tj
-32.8873 -1.2983 Td
(have)Tj
2.0579 0 Td
(previously)Tj
4.354 0 Td
(been)Tj
2.1203 0 Td
(shown)Tj
2.8459 0 Td
(to)Tj
1.0262 0 Td
(be)Tj
1.1508 0 Td
(three)Tj
2.2677 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(most)Tj
2.2053 0 Td
(immunogenic)Tj
5.8394 0 Td
(CMV)Tj
2.4661 0 Td
(proteins)Tj
3.5149 0 Td
([)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(])Tj
1.8539 0 Td
(and)Tj
1.7291 0 Td
(are)Tj
-35.9147 -1.2983 Td
(important)Tj
4.2802 0 Td
(for)Tj
1.389 0 Td
(the)Tj
1.4683 0 Td
(structural)Tj
4.0762 0 Td
(assembly)Tj
3.8268 0 Td
(and)Tj
1.7348 0 Td
(replicative)Tj
4.3426 0 Td
(capacity)Tj
3.4753 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(virus)Tj
2.1997 0 Td
([)Tj
0.83 0.64 0.02 0 k
(19)Tj
0 g
(].)Tj
-0.005 Tc
-28.0798 -1.3039 Td
(We)Tj
1.61 0 Td
(used)Tj
2.058 0 Td
(a)Tj
0.6519 0 Td
(combination)Tj
5.3348 0 Td
(of)Tj
1.0148 0 Td
(ELISpot)Tj
3.4582 0 Td
(assays,)Tj
2.8403 0 Td
(peptide-HLA)Tj
5.5276 0 Td
(class)Tj
2.0409 0 Td
(I)Tj
0.5556 0 Td
(binding)Tj
3.3448 0 Td
(studies,)Tj
3.2032 0 Td
(bioinfor-)Tj
-32.8363 -1.2982 Td
(matic)Tj
2.4547 0 Td
(prediction)Tj
4.3654 0 Td
(and)Tj
1.7234 0 Td
(peptide-HLA-Class)Tj
7.937 0 Td
(I)Tj
0.5556 0 Td
(tetramer)Tj
3.6566 0 Td
(studies)Tj
2.9764 0 Td
(to)Tj
1.0261 0 Td
(predict)Tj
3.0387 0 Td
(and)Tj
1.7292 0 Td
(confirm)Tj
3.4355 0 Td
(novel)Tj
-32.8986 -1.2983 Td
(CD8+)Tj
2.6702 0 Td
(T)Tj
0.8277 0 Td
(cell)Tj
1.559 0 Td
(epitopes)Tj
3.5263 0 Td
(in)Tj
1.0318 0 Td
(CMV.)Tj
2.6929 0 Td
(In)Tj
1.1055 0 Td
(this)Tj
1.6724 0 Td
(way,)Tj
2.0126 0 Td
(we)Tj
1.3266 0 Td
(have)Tj
2.058 0 Td
(determined)Tj
4.8415 0 Td
(the)Tj
1.4627 0 Td
(immunodominant)Tj
7.6478 0 Td
(CMV-)Tj
-34.435 -1.3039 Td
(specific)Tj
3.1804 0 Td
(CD8+)Tj
2.6702 0 Td
(T-cell)Tj
2.5172 0 Td
(responses)Tj
4.0875 0 Td
(in)Tj
1.0318 0 Td
(a)Tj
0.652 0 Td
(Southern)Tj
3.8948 0 Td
(African)Tj
3.2258 0 Td
(cohort)Tj
2.8516 0 Td
(and)Tj
1.7234 0 Td
(defined)Tj
3.2202 0 Td
(16)Tj
1.1735 0 Td
(novel)Tj
2.3924 0 Td
(predicted)Tj
-32.6208 -1.2983 Td
(CMV-specific)Tj
5.7769 0 Td
(CD8+)Tj
2.6702 0 Td
(T-cell)Tj
2.5172 0 Td
(epitopes)Tj
3.5263 0 Td
(within)Tj
2.8062 0 Td
(pp65,)Tj
2.4265 0 Td
(IE-1)Tj
1.9559 0 Td
(and)Tj
1.7234 0 Td
(IE-2,)Tj
2.177 0 Td
(in)Tj
1.0318 0 Td
(three)Tj
2.2621 0 Td
(cases)Tj
2.2166 0 Td
(confirming)Tj
4.7169 0 Td
(the)Tj
-35.807 -1.2983 Td
(optimal)Tj
3.2995 0 Td
(epitope)Tj
3.1691 0 Td
(and)Tj
1.7291 0 Td
(HLA)Tj
2.2053 0 Td
(restriction)Tj
4.3484 0 Td
(using)Tj
2.381 0 Td
(peptide-HLA)Tj
5.5276 0 Td
(class)Tj
2.0409 0 Td
(I)Tj
0.5556 0 Td
(tetramers.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 324 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Material)Tj
3.959 0 Td
(and)Tj
1.989 0 Td
(methods)Tj
/F0 1 Tf
-5.948 -1.5023 Td
(Study)Tj
2.7543 0 Td
(subjects)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 289.0204 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(We)Tj
1.61 0 Td
(studied)Tj
3.1521 0 Td
(257)Tj
1.6441 0 Td
(HIV-infected)Tj
5.5729 0 Td
(ART-naive)Tj
4.6148 0 Td
(adult)Tj
2.2563 0 Td
(and)Tj
1.7291 0 Td
(paediatric)Tj
4.184 0 Td
(subjects)Tj
3.3788 0 Td
(recruited)Tj
3.8551 0 Td
(via)Tj
1.3777 0 Td
(three)Tj
2.262 0 Td
(pre-)Tj
-35.6369 -1.3039 Td
(viously)Tj
3.0387 0 Td
(described)Tj
4.0478 0 Td
(cohorts)Tj
3.2202 0 Td
(\()Tj
0.83 0.64 0.02 0 k
(Table)Tj
2.7779 0 Td
(1)Tj
0 g
(\):)Tj
-13.0846 -1.8992 Td
(1.)Tj
1.2018 0 Td
(Kimberley,)Tj
4.6318 0 Td
(South)Tj
2.5568 0 Td
(Africa,)Tj
2.9084 0 Td
(n)Tj
0.771 0 Td
(=)Tj
0.7994 0 Td
(69)Tj
1.1735 0 Td
([)Tj
0.83 0.64 0.02 0 k
(20)Tj
0 g
(])Tj
-14.0427 -1.8992 Td
(2.)Tj
1.2018 0 Td
(Durban,)Tj
3.566 0 Td
(South)Tj
2.5568 0 Td
(Africa,)Tj
2.914 0 Td
(n)Tj
0.771 0 Td
(=)Tj
0.7994 0 Td
(84)Tj
1.1679 0 Td
([)Tj
0.83 0.64 0.02 0 k
(21)Tj
0 g
(])Tj
-12.9769 -1.8992 Td
(3.)Tj
1.2018 0 Td
(Thames)Tj
3.3959 0 Td
(Valley)Tj
2.7156 0 Td
(cohort)Tj
2.8573 0 Td
(\(southern)Tj
4.1272 0 Td
(African)Tj
3.2372 0 Td
(subjects)Tj
3.3732 0 Td
(attending)Tj
4.0365 0 Td
(outpatient)Tj
4.337 0 Td
(HIV)Tj
2.0239 0 Td
(clinics)Tj
2.7552 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
-33.8965 -1.2982 Td
(Thames)Tj
3.3959 0 Td
(Valley)Tj
2.7156 0 Td
(area)Tj
1.8879 0 Td
(of)Tj
1.0147 0 Td
(the)Tj
1.4684 0 Td
(U.K,)Tj
2.0806 0 Td
(originating)Tj
4.6601 0 Td
(from)Tj
2.2054 0 Td
(Botswana,)Tj
4.2916 0 Td
(Malawi,)Tj
3.4016 0 Td
(South)Tj
2.5568 0 Td
(Africa,)Tj
2.914 0 Td
(Kenya,)Tj
-32.5926 -1.304 Td
(Zambia)Tj
3.2825 0 Td
(and)Tj
1.7292 0 Td
(Zimbabwe\),)Tj
5.0286 0 Td
(n)Tj
0.7653 0 Td
(=)Tj
0.7994 0 Td
(104)Tj
1.6498 0 Td
([)Tj
0.83 0.64 0.02 0 k
(22)Tj
0 g
(].)Tj
-13.2604 -3.1974 Td
(In)Tj
1.1111 0 Td
(total,)Tj
2.2281 0 Td
(we)Tj
1.3266 0 Td
(used)Tj
2.0636 0 Td
(62)Tj
1.1678 0 Td
(paediatric)Tj
4.1839 0 Td
(\(all)Tj
1.4911 0 Td
(from)Tj
2.2053 0 Td
(the)Tj
1.4683 0 Td
(Kimberley)Tj
4.4051 0 Td
(cohort\))Tj
3.1974 0 Td
(and)Tj
1.7291 0 Td
(195)Tj
1.6441 0 Td
(adult)Tj
2.2564 0 Td
(subject)Tj
3.016 0 Td
(sam-)Tj
-34.6901 -1.2983 Td
(ples)Tj
1.7688 0 Td
(for)Tj
1.3833 0 Td
(ELISpot)Tj
3.4639 0 Td
(studies.)Tj
3.2144 0 Td
(We)Tj
1.6101 0 Td
(used)Tj
2.0579 0 Td
(an)Tj
1.2019 0 Td
(additional)Tj
4.2803 0 Td
(37)Tj
1.1679 0 Td
(subject)Tj
3.0217 0 Td
(samples)Tj
3.3789 0 Td
(from)Tj
2.2053 0 Td
(Durban)Tj
3.3449 0 Td
(cohort)Tj
2.8573 0 Td
(for)Tj
-34.9566 -1.3039 Td
(NW8-tetramer)Tj
6.1851 0 Td
(staining.)Tj
3.6397 0 Td
(The)Tj
1.7801 0 Td
(samples)Tj
3.3846 0 Td
(were)Tj
2.1203 0 Td
(collected)Tj
3.7417 0 Td
(between)Tj
3.5262 0 Td
(20092014.)Tj
4.7679 0 Td
(HIV)Tj
2.0239 0 Td
(viral)Tj
1.9899 0 Td
(load)Tj
1.9332 0 Td
(was)Tj
-35.0926 -1.2983 Td
(measured)Tj
4.1045 0 Td
(using)Tj
2.3924 0 Td
(the)Tj
1.4684 0 Td
(Roche)Tj
2.7269 0 Td
(Amplicor)Tj
4.0535 0 Td
(version)Tj
3.1521 0 Td
(1.5)Tj
1.4003 0 Td
(assay)Tj
2.262 0 Td
(according)Tj
4.1896 0 Td
(the)Tj
1.4683 0 Td
(manufacturer's)Tj
6.2646 0 Td
(instruc-)Tj
-33.4826 -1.2982 Td
(tions;)Tj
2.4264 0 Td
(CD4+)Tj
2.6759 0 Td
(T-cell)Tj
2.5171 0 Td
(counts)Tj
2.8913 0 Td
(were)Tj
2.1204 0 Td
(measured)Tj
4.1102 0 Td
(by)Tj
1.1792 0 Td
(flow)Tj
1.9445 0 Td
(cytometry.)Tj
4.4957 0 Td
(The)Tj
1.7859 0 Td
(CD4%)Tj
2.8516 0 Td
(is)Tj
0.8447 0 Td
(calculated)Tj
4.2066 0 Td
(as)Tj
1.0148 0 Td
(the)Tj
-35.0643 -1.304 Td
(percentage)Tj
4.5467 0 Td
(of)Tj
1.0148 0 Td
(live)Tj
1.6101 0 Td
(CD3+)Tj
2.6758 0 Td
(CD4+)Tj
2.6759 0 Td
(T-cells)Tj
2.88 0 Td
(in)Tj
1.0375 0 Td
(total)Tj
2.0069 0 Td
(lymphocytes.)Tj
5.4765 0 Td
(The)Tj
1.7802 0 Td
(CD4%)Tj
2.8573 0 Td
(percentages)Tj
4.9095 0 Td
(in)Tj
1.0318 0 Td
(chil-)Tj
-34.503 -1.2982 Td
(dren)Tj
2.0919 0 Td
(were)Tj
2.1203 0 Td
(recorded)Tj
3.7984 0 Td
(at)Tj
0.9524 0 Td
(the)Tj
1.4684 0 Td
(recruitment)Tj
4.9889 0 Td
(site.)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 223.9937 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Immuno)Tj
3.5575 0 Td
(dominant)Tj
4.2661 0 Td
(cytomeg)Tj
3.7205 0 Td
(alovirus-s)Tj
4.1953 0 Td
(pecific)Tj
3.0048 0 Td
(CD8+)Tj
2.7638 0 Td
(T-cell)Tj
2.615 0 Td
(responses)Tj
4.7551 0 Td
(in)Tj
0.978 0 Td
(sub-Sahara)Tj
5.0811 0 Td
(n)Tj
0.7654 0 Td
(African)Tj
3.2811 0 Td
(populations)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.01896)Tj
4.089 0 Td
(12)Tj
0 g
2.0906 0 Td
(December)Tj
4.7622 0 Td
(12,)Tj
1.5875 0 Td
(2017)Tj
32.5561 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
ET
endstream
endobj
36 0 obj
<>stream
endstream
endobj
37 0 obj
<>stream
endstream
endobj
38 0 obj
<>stream
endstream
endobj
39 0 obj
<>stream
endstream
endobj
40 0 obj
<>stream
endstream
endobj
41 0 obj
<>stream
endstream
endobj
42 0 obj
<>stream
endstream
endobj
43 0 obj
<>stream
endstream
endobj
44 0 obj
<>stream
endstream
endobj
45 0 obj
<>stream
endstream
endobj
46 0 obj
<>stream
endstream
endobj
47 0 obj
<>stream
endstream
endobj
48 0 obj
<>stream
endstream
endobj
49 0 obj
<>stream
endstream
endobj
50 0 obj
<>stream
endstream
endobj
51 0 obj
<>stream
endstream
endobj
52 0 obj
<>stream
endstream
endobj
53 0 obj
<>stream
endstream
endobj
54 0 obj
<>stream
endstream
endobj
55 0 obj
<>stream
BT
66.402 0 Td
(15)Tj
ET
Q
endstream
endobj
56 0 obj
<>/ColorSpace<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 11 0 R/Annots 62 0 R/Contents 63 0 R/TrimBox[0 0 612 792]>>
endobj
61 0 obj
[/ICCBased 64 0 R]
endobj
64 0 obj
<>stream
xwTSϽ7PkhRH
H.*1 J "6DTpDQ2(C"QDqpIdy͛~kg}ֺ LX Xňg` l pBF|،l *? Y"1 P\8=W%Oɘ4M0J"Y2Vs,[|e92<se'9`2&ctI@o|N6 (.sSdl-c(2-y H_/XZ.$&\SM07#1ؙYr fYym";8980m-m(]v^DW~
emi ]P`/ u}q|^R,g+\Kk)/C_|Rax8t1C^7nfzDp柇u$/ED˦L L[B@ٹЖX!@~ (* {d+}G͋љς}WL$cGD2QZ4 E@@ A(q`1D `'u46ptc48.`R0)
@Rt CXCP%CBH@Rf[(t
CQhz#0 Zl`O828.p|O×X
?:0FBx$ !i@ڐH[EE1PL⢖V6QP>U(j
MFk t,:.FW8c1L&ӎ9ƌaX:
rbl1
{{{;}#tp8_\8"Ey.,X%%Gщ1-9ҀKl.oo/O$&'=JvMޞ